AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Haemonetics Reports Q1 FY26 Earnings; Conference Call Scheduled for Aug. 7.
ByAinvest
Thursday, Aug 7, 2025 6:20 am ET1min read
• Haemonetics releases Q1 FY26 financial results online. • Conference call and webcast set for August 7, 2025. • Results available on Investor Relations website. • Live webcast accessible via Haemonetics' investor relations website.
Haemonetics Corporation (NYSE: HAE) has announced the availability of its first quarter fiscal year 2026 financial results on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on August 7, 2025, at 8:00 a.m. ET to discuss the results. The conference call requires pre-registration, and participants are recommended to join 10 minutes before the event. A replay of the conference call and webcast will be accessible for one year starting from August 7, 2025, at 11:00 a.m. ET.The results show a decrease in revenue of $321 million, a 4% organic revenue increase, and a 12.9% organic ex-CSL revenue increase. Earnings per diluted share stood at $0.70, with adjusted earnings per diluted share at $1.10. Cash flow from operating activities was $17 million, and free cash flow was $2 million. Gross margin was 59.8% in the first quarter of fiscal 2026 compared to 52.0% in the first quarter of fiscal 2025.
Operating expenses increased by $3.2 million or 2.4% compared to the first quarter of fiscal 2025, driven by increased investments in research and development. The income tax rate was 25% in the first quarter of fiscal 2026, compared to 18% in the first quarter of fiscal 2025.
Haemonetics reaffirmed its previous fiscal 2026 GAAP total revenue and organic revenue growth guidance. The company also reaffirmed its adjusted operating margin guidance, adjusted earnings per diluted share guidance, and free cash flow guidance.
The webcast and conference call will provide further insights into the company's performance and future plans. Investors and analysts are encouraged to participate and access the replay for detailed analysis.
References:
[1] https://www.stocktitan.net/news/HAE/haemonetics-1st-quarter-fiscal-year-2026-earnings-release-32i3x2nuiovt.html
[2] https://www.marketscreener.com/news/haemonetics-q1-2026-haemonetics-corporation-earnings-release-ce7c5edfdb88f321
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet